Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 218
Filter
1.
BMC Urol ; 22(1): 197, 2022 Nov 30.
Article in English | MEDLINE | ID: mdl-36451163

ABSTRACT

BACKGROUND: Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumours(EWS/pPNETs) of the kidney are rare. Signs and symptoms are atypical in EWS patients. Presenting symptoms include haematuria, abdominal pain, or a palpable mass. A comprehensive review of the literature shows that it is difficult to make an accurate diagnosis based on physical examination alone. The imaging findings of EWS/pPNETs are nonspecific. We used contrast-enhanced ultrasound (CEUS) to diagnose an EWS/pPNET in our patient, which had never been reported previously to our knowledge. CASE PRESENTATION: This article reports the case of a 20-year-old female with an abdominal mass and gross haematuria for 1 month. The ultrasound revealed a hypoechoic mass with a clear margin at the lower pole in the left kidney. CEUS demonstrated signs of annular enhancement and heterogeneous enhancement of the tumour, and simultaneous wash-in was predominant. Computed tomography images showed an elliptical low-density tumour. The patient underwent a left kidney resection, and the pathological diagnosis was an EWS/pPNET. Twenty-one days after the kidney operation, the patient underwent 8 cycles of a CAV (vinorelbine, ifosfamide, epirubicin) + IE (isocyclophosphamide, etoposide) chemotherapy regimen. Subsequently, radiotherapy (dose: 45 Gy, radiation field:the tumour bed following surgical resection) was administered for nearly 30 days. The patient had no signs of local recurrence or metastasis within a follow-up of 4 years. CONCLUSIONS: As a radiation-free, inexpensive, convenient, and repeatable examination method, ultrasound was the primary choice for kidney examination. Early CEUS was helpful to make an accurate diagnosis. Surgery and adjuvant radiation or chemotherapy administered in a timely manner can prevent further deterioration.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Sarcoma, Ewing , Female , Humans , Young Adult , Adult , Hematuria , Sarcoma, Ewing/diagnostic imaging , Sarcoma, Ewing/therapy , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Kidney/diagnostic imaging , Nephrectomy
2.
Malays J Pathol ; 44(1): 93-99, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35484891

ABSTRACT

INTRODUCTION: Ewing sarcoma (ES), the neuroectodermal derived tumour typically occurs in the bone and soft tissue of children and young adults. Primary ES of the kidney is strikingly rare and only a few cases and small case series have been documented. Due to the highly aggressive nature of this neoplasm, distinction from other morphological mimickers is truly indispensable in terms of treatment and prognosis. Here we describe the clinicopathological features of four cases of primary ES of the kidney with special emphasis on one case having extensive neural differentiation postneo- adjuvant chemotherapy (NACT). Extensive neural differentiation in renal ES has not been documented to date. CASE SERIES: Four patients (age range from 15-35 years) had kidney mass and multiple distant metastases at first presentation. Primary diagnosis of Ewing sarcoma was rendered by histopathology with the help of immunohistochemistry on core biopsy material. Tumour cells in all cases showed diffuse membranous CD99, nuclear FLI-1 and NKX2.2. Two of the patients had undergone radical nephrectomy followed by combination chemotherapy. Another two patients were first treated with neo-adjuvant chemotherapy (NACT) followed by radical nephrectomy. In one of them, histopathological examination of nephrectomy specimens revealed extensive neural differentiation. The adrenal gland was free in all four cases. The follow-up period was 12 -24 months. Three patients had survived and one of them became disease-free. CONCLUSION: Primary ES of the kidney is a rare and lethal entity. Due to overwhelming rarity, chemotherapy protocol has not been standardised and followed as ES in bone/soft tissue. Histopathological confirmation and prompt initiation of treatment may improve patient survival and outcome.


Subject(s)
Kidney Neoplasms , Neuroectodermal Tumors, Primitive, Peripheral , Neuroectodermal Tumors, Primitive , Sarcoma, Ewing , Adult , Female , Humans , Kidney/pathology , Kidney Neoplasms/diagnosis , Male , Neuroectodermal Tumors, Primitive/diagnosis , Neuroectodermal Tumors, Primitive/pathology , Neuroectodermal Tumors, Primitive/therapy , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/diagnosis , Sarcoma, Ewing/therapy , Young Adult
3.
Folia Neuropathol ; 60(1): 128-136, 2022.
Article in English | MEDLINE | ID: mdl-35359153

ABSTRACT

Peripheral primitive neuroectodermal tumours (PNETs) are rare and highly malignant tumours in the spine, with a predilection for young adults. There are no standard guidelines for treating these tumours. Surgical resection combined with postoperative radiotherapy and chemotherapy is a common and effective treatment at present. Even so, survival time of patients with these tumours is still very short. In this study, we present three rare cases of thoracic epidural PNETs and review the literature.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Neuroectodermal Tumors, Primitive , Humans , Neuroectodermal Tumors, Primitive/pathology , Neuroectodermal Tumors, Primitive/surgery , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Treatment Outcome , Young Adult
4.
Eur J Ophthalmol ; 32(3): NP23-NP27, 2022 May.
Article in English | MEDLINE | ID: mdl-33499663

ABSTRACT

INTRODUCTION: Primitive neuroectodermal tumors arise from the progenitor cells of the neural crest, in the central nervous system or other peripheral locations. CASE PRESENTATION: We report a rare case of a congenital malignant tumor, diagnosed as a primary orbital primitive neuroectodermal tumor on histopathological examination. CONCLUSION: Multidisciplinary management with adjuvant chemotherapy needed for the management of these cases.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Neuroectodermal Tumors, Primitive , Sarcoma, Ewing , Chemotherapy, Adjuvant , Humans , Infant, Newborn , Neuroectodermal Tumors, Primitive/diagnosis , Neuroectodermal Tumors, Primitive/therapy , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Orbit/pathology , Sarcoma, Ewing/diagnosis , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/pathology
5.
BMC Cardiovasc Disord ; 21(1): 305, 2021 06 16.
Article in English | MEDLINE | ID: mdl-34134636

ABSTRACT

BACKGROUND: The primitive neuroectodermal tumors (PNETs) are a family of highly malignant tumors with a multidirectional differential potential. The tumors are characterized by aggressive small round tumor cells that originate from the spinal cord of the central and sympathetic nervous systems. Cases involving the pericardium are extremely rare. Herein, we present a case of peripheral primitive neuroectodermal tumor (pPNET) that originated in the pericardium. CASE PRESENTATION: A 23-year-old woman presented with cough and progressive dyspnea for 1 month, followed by eyelid and facial edema for 10 days, without any apparent cause. Significantly elevated tumor markers were detected in her blood. A cardiac ultrasound revealed a 74 mm × 61 mm spherical mass that was attached to the left pericardium, as well as massive pericardial effusion. Positron emission tomography-CT (PET-CT) showed focal hypermetabolism in the left pericardium. Via histopathology and immunohistochemistry, the spherical mass was identified as PNETS. The patient was successfully treated with a combination of surgical resection via thoracotomy and postoperative chemotherapy, and she was disease-free for 7 years at follow-up. Unfortunately, at 7 years after the treatment, the patient's pPNET recurred. Positron emission tomography-MRI (PET-MRI) and 64-slice coronary CTA revealed that the aorta and multiple coronary arteries were involved. Subsequently, the patient refused a heart transplant and voluntarily left the hospital. CONCLUSIONS: This paper reports on a rare and recurrent case of PNET in the parietal pericardium. With respect to the different biologic characteristics and prognoses of pPNETs (compared to other known pericardium tumors), it is essential to consider this entity as a differential diagnosis in pericardium tumors.


Subject(s)
Heart Neoplasms/pathology , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Pericardium/pathology , Cardiac Surgical Procedures , Chemotherapy, Adjuvant , Female , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/therapy , Humans , Neoplasm Recurrence, Local , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Pericardium/diagnostic imaging , Pericardium/surgery , Time Factors , Treatment Outcome , Young Adult
6.
Taiwan J Obstet Gynecol ; 60(1): 142-144, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33494989

ABSTRACT

OBJECTIVE: Ewing sarcoma is a type of neuroectodermal tumors (Ewing family of tumors-EFT) that mostly affect the bone or soft tissue. Primary uterine Ewing sarcoma is extremely rare. CASE REPORT: We report a case of a primary uterine Ewing sarcoma in a 46-year-old patient, treated with total abdominal hysterectomy, and bilateral salpingo-oophorectomy and following adjuvant chemotherapy with 6 cycles of vincristine, doxorubicin, and cyclophosphamide, achieving complete remission for one year. CONCLUSION: Complete resection for EFT is the first choice of treatment, regardless of their origins. Adjuvant chemotherapy or radiotherapy is mandatory if needed. Due to rarity of the disease, this report re-emphasizes the accurate diagnosis and appropriate treatment for these unusual tumor types occurred in female genital organs.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/therapy , Uterine Neoplasms/therapy , Chemotherapy, Adjuvant , Female , Humans , Hysterectomy , Medical Illustration , Middle Aged , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Sarcoma, Ewing/pathology , Uterine Neoplasms/pathology , Uterus/pathology
7.
Childs Nerv Syst ; 37(3): 839-849, 2021 03.
Article in English | MEDLINE | ID: mdl-32761378

ABSTRACT

PURPOSE: The purpose is to highlight the primary intracranial (meningeal-based) occurrence of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET). METHODS: This report is a collation of clinicopathological features of eight cases of molecularly and clinicoradiologically confirmed primary (non-metastatic) intracranial (non-osseous) meningeal ES/PNET. RESULTS: The age range was 1 to 33 years with a median age of 9 years. Male to female ratio was 0.6:1. All patients were diagnosed on the debulking surgical material (gross total resection, 2 cases; subtotal resection, 6 cases) and showed primitive embryonal histomorphology with diffuse membranous CD99 immunoexpression and EWSR1 gene rearrangement by fluorescence in situ hybridization. Seven of them showed a typical FISH pattern of split signals with break-apart probe, while one showed an unusual signal pattern of loss of green signals. EFT-2001 adjuvant protocol was followed along with focal radiotherapy (RT) in all cases (except case 8, full course of chemotherapy could not be completed). Two cases had local recurrence-one of them died of disease recurrence before the administration of further treatment. CONCLUSION: This series adds non-osseous intracranial site to the list of uncommon sites of occurrence for ES/PNET and more importantly emphasizes the need to be considered in a differential list of primary intracranial primitive embryonal tumors before embarking as primary central nervous system (CNS) embryonal tumor, NOS.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Neuroectodermal Tumors, Primitive , Sarcoma, Ewing , Adolescent , Adult , Biomarkers, Tumor , Child , Child, Preschool , Female , Humans , In Situ Hybridization, Fluorescence , Infant , Male , Neoplasm Recurrence, Local , Neuroectodermal Tumors, Primitive/diagnostic imaging , Neuroectodermal Tumors, Primitive/therapy , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/genetics , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/diagnostic imaging , Sarcoma, Ewing/genetics , Sarcoma, Ewing/therapy , Young Adult
8.
Sci Rep ; 10(1): 15656, 2020 09 24.
Article in English | MEDLINE | ID: mdl-32973274

ABSTRACT

Peripheral primitive neuroectodermal tumors (PNETs) constitute very rare and aggressive malignancies. To date, there are no standard guidelines for management of peripheral PNETs due to the paucity of cases arising in various body sites. Therapeutic approach is derived from Ewing sarcoma family, which currently remains multimodal. Our study retrospectively analyzed 86 PNET patients from February 1, 1998 to February 1, 2018 at Peking Union Medical College Hospital with an additional 75 patients from review of literature. The clinicopathologic and treatment plans associated with survival was investigated. Surgery, chemotherapy, female sex, small tumor size, no lymph node metastasis, R0 surgical resection, (vincristine + doxorubicin + cyclophosphamide)/(isophosphamide + etoposide) regimen, and more than 10 cycles of chemotherapy were associated with improved overall survival in univariate analysis. Surgery, more than 10 cycles of chemotherapy, and small tumor size were independent prognostic factors for higher overall survival. Our data indicates that multimodal therapy is the mainstay therapeutic approach for peripheral PNET.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral/therapy , Adolescent , Adult , Combined Modality Therapy , Female , Humans , Male , Neuroectodermal Tumors, Primitive, Peripheral/drug therapy , Neuroectodermal Tumors, Primitive, Peripheral/radiotherapy , Survival Analysis , Treatment Outcome , Young Adult
9.
J Obstet Gynaecol Res ; 46(10): 2185-2192, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32761741

ABSTRACT

Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumors (pPNET) are soft tissue tumors that generally affect the bones. Extraosseous ES/pPNET has been rarely reported. Our patient presented with a 6 × 4 cm right subcutaneous solid vulvar lesion causing pain and discomfort. Pathology and immunohistochemistry staining showed strong positivity for CD99 and vimentin, favoring the diagnosis of ES/pPNET. Magnetic resonance imaging showed a 6-cm lesion in the right vulvar region with enlarged bilateral inguinal and right iliac lymph nodes. Fluorescence in situ hybridization test for translocation t(11;22)(q24;q12) was positive, confirming the diagnosis. The patient received three cycles of neoadjuvant chemotherapy with vincristine, adriamycin, cyclophosphamide alternating with ifosfamide and etoposide with complete response. The patient underwent vulvar radical local excision. Residual tumor measured 1.6 cm with free margins. She received four additional cycles of adjuvant chemotherapy and 30 sessions radiotherapy. She is currently disease free after 37 months. No ES/pPNET cases with pelvic lymph nodes metastasis were ever reported.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Sarcoma, Ewing , Chemotherapy, Adjuvant , Female , Humans , In Situ Hybridization, Fluorescence , Lymph Nodes , Neuroectodermal Tumors, Primitive, Peripheral/diagnosis , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/diagnosis , Sarcoma, Ewing/therapy
10.
J BUON ; 24(2): 770-778, 2019.
Article in English | MEDLINE | ID: mdl-31128035

ABSTRACT

PURPOSE: Ewing Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET) is a malignant small round cell tumor belonging to the Ewing Sarcoma Family of Tumors. It occurs more commonly in children and young adults. Its localization in the adrenal gland is extremely rare. We reviewed 35 cases of ES/PNET of the adrenal gland reported in the literature and presented our case. METHODS: Data were collected by searching for ES/PNET and adrenal gland key words on Google Scholar and PubMed in March 2018, including a case diagnosed in our department. We analyzed all reviewed cases for diagnosis, surgical and systemic therapy and outcome. RESULTS: To date 24 articles presenting cases of ES/PNET of the adrenal gland are reported in the literature. We included in our review 35 cases previously described and one new case. Histologically all cases consisted of sheets of small round cells. Immunohistochemistry was also performed in all cases. Most cases stained positive for CD99 and negative for lymphocytic markers. Markers of epithelial differentiation displayed variable results. In all cases tested, characteristic translocations were displayed supporting the diagnosis. All patients but four were treated surgically and the majority received adjuvant therapy. Only very few cases received neoadjuvant chemotherapy. CONCLUSIONS: Primary ES/PNET of the adrenal gland is a rare tumor, showing specific morphological, immunohistochemical and cytogenetic characteristics. Treatment consists of surgery, chemotherapy and radiotherapy. Further investigations paired with long term follow-up are necessary to define prognosis for this rare entity.


Subject(s)
12E7 Antigen/genetics , Adrenal Gland Neoplasms/epidemiology , Neuroectodermal Tumors, Primitive, Peripheral/epidemiology , Sarcoma, Ewing/epidemiology , Adolescent , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/therapy , Adrenal Glands/pathology , Adult , Child , Child, Preschool , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Male , Middle Aged , Neuroectodermal Tumors, Primitive, Peripheral/genetics , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Prognosis , Sarcoma, Ewing/genetics , Sarcoma, Ewing/pathology , Sarcoma, Ewing/therapy , Young Adult
11.
Int J Gynecol Pathol ; 38(5): 470-473, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30085939

ABSTRACT

Ewing sarcoma and peripheral primitive neuroectodermal tumor constitute the Ewing family of tumors (EFT). EFTs primarily arising in the ovary are extremely rare. We report the case of a 22-yr-old nulliparous woman with a primary EFT in the ovary that initially presented as a 3-cm teratoma-like ovarian tumor, with rapid progression to a 15-cm-sized tumor with liver metastasis in 3 mo. The patient underwent suboptimal debulking surgery and salvage chemotherapy with vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide. In conclusion, primary EFT in the ovary is extremely rare with highly aggressive behavior and poor outcome for metastatic disease. Demonstration of EWSR1 rearrangement, observed in a variety of soft tissue tumors, is very helpful in the diagnosis of EFT when interpreted on the basis morphology and immunohistochemistry.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral/pathology , Ovarian Neoplasms/pathology , Sarcoma, Ewing/pathology , Adult , Female , Humans , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Ovarian Neoplasms/therapy , Sarcoma, Ewing/therapy
12.
World Neurosurg ; 122: e1606-e1614, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30496933

ABSTRACT

OBJECTIVE: Primary intracranial Ewing sarcoma (ES)/peripheral primitive neuroectodermal tumors (pPNETs) are extremely rare, and only a few studies have reported >4 cases of this disease. The purpose of this study was to explore the clinical features, treatment, and outcome of primary intracranial ES/pPNETs. METHODS: The clinical data of 14 patients who had been surgically treated from February 2003 to November 2017 and in whom immunohistochemical staining results had confirmed the diagnosis of primary intracranial ES/pPNETs were retrospectively analyzed. Kaplan-Meier survival analysis was used to estimate the survival rate and the median survival time (MST). RESULTS: Gross total resection (GTR) was achieved in 7 cases, and subtotal resection was performed in 7 cases. During follow-up, 10 (71.4%) patients had local recurrence and 3 (21.4%) patients had distant metastasis. The overall 1-, 2-, and 5-year survival rates were 78.6%, 47.6%, and 19.0%, respectively. Kaplan-Meier survival analysis showed that postoperative radiotherapy was a significant prognostic factor for longer MST (P = 0.034). GTR and radiotherapy with or without adjuvant chemotherapy yielded the highest 2-year survival rate (100%). Three patients who underwent GTR, radiotherapy, and chemotherapy had the highest 2-year survival rates (100%) and the longest MST (48 months). CONCLUSIONS: Primary intracranial ES/pPNETs have an aggressive clinical course, with a high tendency for local recurrence and distant metastasis. Radiotherapy plays a significant role in improving the survival of patients. GTR combined with radiotherapy and chemotherapy may be the most beneficial treatment modality.


Subject(s)
Bone Neoplasms/therapy , Brain Neoplasms/therapy , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/therapy , Adult , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/mortality , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Prognosis , Sarcoma, Ewing/diagnostic imaging , Sarcoma, Ewing/mortality , Sarcoma, Ewing/pathology , Treatment Outcome , Young Adult
13.
Can J Urol ; 25(5): 9530-9533, 2018 10.
Article in English | MEDLINE | ID: mdl-30281013

ABSTRACT

A 26-year-old male with a personal history of schizophrenia initially presented with a 13 cm pelvic mass corresponding to a cryptorchidic testis. The patient was treated with primary and second-line chemotherapy for metastatic germ-cell tumor followed by surgical consolidation. Final pathology revealed a primitive neuroectodermal tumor (PNET) mixed with mature teratoma. Despite multidisciplinary management, significant patient non-compliance led to inadequate follow up and treatment delays ultimately resulting in death. To our knowledge, this is the only reported case of teratoma with malignant transformation arising from an untreated congenital undescended testicle.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral/secondary , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Patient Compliance , Testicular Neoplasms/pathology , Testicular Neoplasms/therapy , Adult , Cryptorchidism/complications , Fatal Outcome , Humans , Lymphatic Metastasis , Male , Neuroectodermal Tumors, Primitive, Peripheral/complications , Schizophrenia/complications , Testicular Neoplasms/complications
14.
Clin Neurol Neurosurg ; 175: 25-33, 2018 12.
Article in English | MEDLINE | ID: mdl-30312956

ABSTRACT

OBJECTIVE: We sought to assess the use of surgical treatment, the effect of postoperative adjuvant therapy, and the prognostic factors for survival of patients with primary spinal peripheral primitive neuroectodermal tumors (pPNETs). PATIENTS AND METHODS: The clinical data of 24 patients, who had been surgically treated from April 2003 to February 2018 and in whom immunohistochemical staining results had confirmed the diagnosis of primary spinal pPNETs, were retrospectively analyzed. To analyze the factors related to prognosis, the Kaplan-Meier method was used for univariate analysis, the log-rank method was used to test the significance of difference, and multivariate analysis was performed using Cox regression. RESULTS: The overall 1-year, 2-year, and 5-year survival rates were 73.2%, 48.1%, and 12.0%, respectively. The median survival time (MST) of all patients was 21 months. Univariate analysis showed that the extent of tumor resection, adjuvant radiotherapy, and chemotherapy were the factors influencing patient prognosis after surgery (all P < 0.05); sex, age, tumor location, and preoperative Karnofsky performance scale (KPS) scores were not the influential factors for prognosis of patients after surgery (all P > 0.05). Multivariate analysis showed that gross total resection (GTR) of tumors and adjuvant radiotherapy were independent factors influencing the prognosis of patients with pPNETs (all P < 0.05). CONCLUSIONS: Primary spinal pPNETs are extremely rare, and they have a poor prognosis. Microsurgical GTR of the tumor is the preferred method of treatment. Radiotherapy plays an important role in improving the prognosis of patients with pPNETs. GTR combined with radiotherapy and chemotherapy may be the best treatment modality.


Subject(s)
Chemoradiotherapy, Adjuvant/trends , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Spinal Neoplasms/diagnostic imaging , Spinal Neoplasms/therapy , Adolescent , Adult , Chemoradiotherapy, Adjuvant/methods , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Radiotherapy, Adjuvant/methods , Radiotherapy, Adjuvant/trends , Survival Rate/trends , Time Factors , Treatment Outcome , Young Adult
15.
World J Surg Oncol ; 16(1): 140, 2018 Jul 13.
Article in English | MEDLINE | ID: mdl-30005673

ABSTRACT

BACKGROUND: We report our experience and outcomes about the management of Askin's tumors [AT], which are rare primitive neuroectodermal tumors (PNETs) that develop within the soft tissue of the thoracopulmonary region, typically in children and adolescents. METHODS: We retrospectively analyzed the charts of 9 patients affected by AT (aged 6-15 years), treated at the Paediatric Oncology Unit of Gemelli University Hospital in Rome between January 2001 and December 2016. RESULTS: All nine patients underwent to biopsy followed by neoadjuvant chemotherapy. At the end of the neoadjuvant chemotherapy, they underwent to surgical removal of the residual tumor. Five patients with positive tumor margins and/or necrosis< 90% received local radiotherapy. Two patients with metastasis received an intensified treatment, with the addition of high dose adjuvant chemotherapy followed by peripheral blood stem cells rescue. No statistically significant correlation was found between outcome and gender; the presence of any metastasis and the radiotherapy. The overall survival was 65.14 months (95% confidence interval [95%CI], 45.81-84.48), and the 5 years survival was 60%, at a median follow-up of 53.1 months. CONCLUSION: Our study confirms that a multimodal treatment with surgery, chemotherapy, and radiotherapy may increase the survival in AT pediatric patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Soft Tissue Neoplasms/therapy , Thoracic Neoplasms/therapy , Adolescent , Bone Neoplasms/diagnosis , Bone Neoplasms/mortality , Child , Combined Modality Therapy , Female , Humans , Male , Neoadjuvant Therapy , Neuroectodermal Tumors, Primitive, Peripheral/diagnosis , Neuroectodermal Tumors, Primitive, Peripheral/mortality , Peripheral Blood Stem Cell Transplantation , Prognosis , Radiotherapy, Adjuvant , Retrospective Studies , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/mortality , Survival Analysis , Thoracic Neoplasms/diagnosis , Thoracic Neoplasms/mortality
16.
Curr Opin Urol ; 28(5): 469-473, 2018 09.
Article in English | MEDLINE | ID: mdl-29939859

ABSTRACT

PURPOSE OF REVIEW: The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST). RECENT FINDINGS: The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse. SUMMARY: Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.


Subject(s)
Adenocarcinoma/therapy , Cell Transformation, Neoplastic , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Rhabdomyosarcoma/therapy , Teratoma/therapy , Testicular Neoplasms/therapy , Adenocarcinoma/secondary , Chemotherapy, Adjuvant , Humans , Lymph Node Excision , Male , Metastasectomy , Neoplasm Recurrence, Local , Neuroectodermal Tumors, Primitive, Peripheral/secondary , Prognosis , Retroperitoneal Space , Rhabdomyosarcoma/secondary , Sarcoma/therapy , Teratoma/secondary , Testicular Neoplasms/pathology
17.
Iran J Kidney Dis ; 12(3): 190-192, 2018 05.
Article in English | MEDLINE | ID: mdl-29891750

ABSTRACT

Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/PNET) typically occurs in long or flat bones, soft tissues, or less often, solid organs. Ewing sarcoma/peripheral primitive neuroectodermal tumor arising from the adrenal gland is extremely rare, especially in children, and only limited cases are reported previously. Herein, we review a case of a 22-month-old girl who presented to our department with abdominal pain, bulging of the left flank, and a nonfunctioning adrenal lesion which was found to be an adrenal ES/PNET. The patient was successfully treated with surgery and adjuvant chemotherapy. Since delayed diagnosis may result in metastatic lesions, this case underscores the importance of considering ES/PNET in the differential diagnosis of large adrenal masses.


Subject(s)
Adrenal Gland Neoplasms/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Sarcoma, Ewing/diagnostic imaging , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/therapy , Chemotherapy, Adjuvant , Diagnosis, Differential , Female , Humans , Infant , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/pathology , Sarcoma, Ewing/therapy , Surgical Procedures, Operative , Tomography, X-Ray Computed
18.
World Neurosurg ; 115: 346-356, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29729469

ABSTRACT

BACKGROUND: Ewing sarcoma (ES) is a malignant bone tumor that is most commonly observed in the long bones, the pelvis, and the chest. Primary intracranial localization is extremely rare. OBJECTIVE: In the aim of identifying the prognostic factors of this rare localization, we conducted a systematic review of the literature for patients with primary intracranial peripheral primitive neuroectodermal tumor/ES. METHODS: A complete MEDLINE search was undertaken for all articles reporting data for primary intracranial peripheral primitive neuroectodermal tumor/ES. We divided the patient population into 2 groups: group I, patients who were free of disease; and group II, patients who died or had uncontrolled disease at the last available follow-up. We conducted a comparative statistical analysis of data between the 2 groups. RESULTS: A total of 48 patients were included in the review. There were 32 patients in group I and 12 in group II. Fifty percent of tumors in group II and only 16% of tumors in group I were infratentotorial (P = 0.03). Signs of bone involvement were observed in 19% of patients in group I and 54% in group II (P = 0.03). Total removal was accomplished in 29% of patients in group I and in no patients in group II (P = 0.03). Radiotherapy was performed in 73% of patients in group II and 81% in group I (P = 0.43). Chemotherapy was administered in 36% of patients in group II and 74% in group I (P = 0.03). CONCLUSIONS: Infratentorial localization and the presence of bone involvement were associated with poor prognosis; Surgery seems to be a predictive factor of prognosis; radiotherapy and chemotherapy must be performed whenever the tumor is not totally removed.


Subject(s)
Bone Neoplasms/diagnostic imaging , Brain Neoplasms/diagnostic imaging , Disease Management , Neuroectodermal Tumors, Primitive/diagnostic imaging , Sarcoma, Ewing/diagnostic imaging , Bone Neoplasms/therapy , Brain Neoplasms/therapy , Humans , Neuroectodermal Tumors, Primitive/therapy , Neuroectodermal Tumors, Primitive, Peripheral/diagnostic imaging , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Prognosis , Sarcoma, Ewing/therapy
19.
Cancer Biol Ther ; 18(1): 4-7, 2017 01 02.
Article in English | MEDLINE | ID: mdl-27905830

ABSTRACT

BACKGROUND: Peripheral primitive neuroectodermal tumor isolated in the heart, presenting as a primary cardiac tumor is considered as extremely rare. METHODS: We present a 53-year-old Chinese female with a cardiac tumor which was discovered by CT. RESULTS: A hypo-intense tumorous mass was shown extending from the left ventricle by Cardiac CT, and fused FDG positron emission tomography demonstrated no other abnormal FDG active lesions in the body. We performed a total resection surgery of the tumor subsequently and the patient recovered well and discharged from hospital 6 d after surgery. CONCLUSION: The pathological diagnosis was primary cardiac peripheral primitive neuroectodermal tumor. No tumor recurrence was shown by echocardiography during the 24 months follow-up visits.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Female , Humans , Middle Aged , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/therapy
20.
Pediatr Neonatol ; 57(5): 436-439, 2016 10.
Article in English | MEDLINE | ID: mdl-24480101

ABSTRACT

Ewing's sarcoma (EWS) and peripheral primitive neuroectodermal tumor (pPNET) are small round cell malignancies that develop in soft tissue and bone. They very rarely affect newborns. A diagnosis of EWS/pPNET depends mainly on immunohistochemistry and molecular/genetic assays. Since these tumors are highly aggressive, patient prognosis is typically very poor, and treatment remains a challenge. Here, we report a 13-day-old newborn diagnosed with congenital EWS/pPNET and describe its treatment.


Subject(s)
Bone Neoplasms/congenital , Bone Neoplasms/pathology , Neuroectodermal Tumors, Primitive, Peripheral/congenital , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Sarcoma, Ewing/congenital , Sarcoma, Ewing/pathology , Bone Neoplasms/therapy , Female , Humans , Immunohistochemistry , Infant, Newborn , Neuroectodermal Tumors, Primitive, Peripheral/therapy , Sarcoma, Ewing/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...